New era of sickle cell treatments reveals persistent system-wide barriers Despite rapid therapeutic advances in sickle cell disease, from red blood cell exchange to gene therapies, delivery remains constrained by infrastructure, geography and care fragmentation. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/new-era-of-sickle-cell-treatments-reveals-persistent-system-wide-barriers-17176 Sickle cell disease (SCD) is the world’s most common monogenic disorder, affecting millions globally. Yet despite its prevalence, it has endured decades of underinvestment and limited therapeutic development, resulting in stark and persistent inequities in care.